Triamide-substituted heterobicyclic compounds
AssigneePfizer Inc.
InventorsPeter Bertinato, Michel Couturier, Ernest Hamanaka, Marcus Ewing, Ralph Robinson, Derek Tickner
Life of this patent
Estimating the term…
Abstract
This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
Claims15
1-22. (canceled)
The compound of the formula
- or a pharmaceutically acceptable salt thereof.
The compound (S)-2-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-quinoline-6-carboxylic acid (pentylcarbamoyl-phenyl-methyl)-amide or a pharmaceutically acceptable salt thereof.
25-27. (canceled)
31-33. (canceled)
A method of treating obesity in an animal, which comprises administering to an animal in need of such treatment a therapeutically effective amount of the compound of the formula
- or a pharmaceutically acceptable salt thereof.
(canceled)
38-39. (canceled)
Crystalline Form A of (S)-2-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-quinoline-6-carboxylic acid (pentylcarbamoyl-phenyl-methyl)-amide having an X-ray powder diffraction pattern having peaks at 2-theta values substantially the same as the 2-theta values for at least ten of the peaks of highest intensity in the X-ray powder diffraction pattern shown in FIG. 1.
Dependencies are inferred from the claim text.